DAR-0100A Uses, Dosage, Side Effects and more
DAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
| Trade Name | DAR-0100A |
| Generic | DAR-0100A |
| DAR-0100A Other Names | Dihydrexidine, (+)- |
| Type | |
| Formula | C17H17NO2 |
| Weight | Average: 267.328 Monoisotopic: 267.125928791 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
